NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization163.23 mln
Float36.94 mln
Earnings Date08/17/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
36
/ 100
Underperforming
Debt / Equity
0.36
Low leverage
ROE
-108
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Acumen Pharmaceuticals is a clinical-stage company working to develop new treatments for Alzheimer's disease. Its lead drug, Sabirnetug, is designed to target a specific form of amyloid-beta protein believed to drive the disease, and is currently being evaluated in a Phase 2 clinical trial following encouraging Phase 1 results. The company is also working with Halozyme to develop a version of the drug that patients could take by injection under the skin rather than through an IV. Founded in 1996 and based in Newton, Massachusetts, Acumen remains focused on bringing meaningful options to patients affected by Alzheimer's.
